Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM.
Candesartan
Drug dose
Heart failure
Sex
Women
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
revised:
11
01
2024
received:
05
10
2023
accepted:
18
01
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
6
4
2024
Statut:
aheadofprint
Résumé
Angiotensin receptor blockers have been shown to reduce heart failure hospitalization and cardiovascular mortality in men and women with heart failure with reduced ejection fraction (HFrEF). It is unknown whether there are differences between men and women in achieved dose and treatment discontinuation due to adverse events of candesartan. We conducted a post hoc analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. A total of 3172 men and 1106 women with HFrEF [left ventricular ejection fraction (LVEF) ≤ 40%] in New York Heart Association class II-IV were randomized to candesartan or placebo. Every 2 weeks, patients were up-titrated from 4 or 8, to16, to 32 mg once daily, unless a higher dose was contraindicated or not tolerated. Women were older (66 vs. 64 years), had a higher LVEF (29.9% vs. 28.6%), and had more hypertension (54% vs. 47%) than men. The mean achieved dose of candesartan was 21.5 ± 12.6 mg in men and 20.7 ± 12.9 mg in women (P = 0.19). In both the candesartan and placebo groups, cardiovascular death and heart failure hospitalizations were higher in men and women who achieved lower dose levels. Event rates for achieved dose levels of 0, 4 or 8, 16, and 32 mg candesartan were 20.8, 17.2, 14.0, and 10.1 per 100 person-years in men, respectively, and 23.6, 13.7, 14.0, and 9.1 per 100 person-years in women, respectively. In each of the achieved dose levels, there was no sex difference in the proportion of patients with an event, neither in the candesartan group nor in the placebo group (P-value for all > 0.05). There was no significant interaction between sex and treatment-related discontinuation for hypotension (P = 0.520), an increase in creatinine (P = 0.102), and hyperkalaemia (P = 0.905). In a randomized clinical trial in patients with HFrEF, men and women achieved similar doses of candesartan. Primary event rates and treatment-related discontinuation due to adverse events were also similar between men and women.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council and University Medical Centre Groningen
ID : 202008440347
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599‐3726. doi:10.1093/eurheartj/ehab368
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627‐3639. doi:10.1093/eurheartj/ehad195
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:895‐1032. doi:10.1161/CIR.0000000000001063
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48:143‐157. doi:10.2165/00003088‐200948030‐00001
Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017;3:163‐182. doi:10.1093/ehjcvp/pvw042
Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol 2016;56:78‐86. doi:10.1002/jcph.571
Brunner HR. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997;10:311S‐317S. doi:10.1016/s0895‐7061(97)00391‐9
Massana E, Barbanoj MJ, Moros C, Morte A, Gich I, Jané F. No sex‐related pharmacokinetic and pharmacodynamic differences of captopril. Pharmacol Res 1997;36:41‐47. doi:10.1006/phrs.1997.0202
Saenz‐Campos D, Bayes MC, Masana E, Martín S, Barbanoj M, Jané F. Sex‐related pharmacokinetic and pharmacodynamic variations of lisinopril. Methods Find Exp Clin Pharmacol 1996;18:533‐538.
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin‐converting‐enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583‐592. doi:10.1056/NEJMoa021716
Rathore SS, Wang Y, Krumholz HM. Sex‐based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403‐1411. doi:10.1056/NEJMoa021266
Fletcher A, Beevers DG, Bulpitt C, Butler A, Coles EC, Hunt D, et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 1988;2:219‐227.
Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender‐related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594‐601. doi:10.1053/cp.1999.v66.103400001
Walle T, Walle UK, Cowart TD, Conradi EC. Pathway‐selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257‐263. doi:10.1038/clpt.1989.136
Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261:1181‐1186.
Zapater P, Novalbos J, Gallego‐Sandin S, Hernandez FT, Abad‐Santos F. Gender differences in angiotensin‐converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol 2004;43:737‐744. doi:10.1097/00005344‐200405000‐00018
McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997;74:181‐194. doi:10.1016/s0163‐7258(97)82002‐5
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: The CHARM‐Alternative trial. Lancet 2003;362:772‐776. doi:10.1016/S0140‐6736(03)14284‐5
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: The CHARM‐Added trial. Lancet 2003;362:767‐771. doi:10.1016/S0140‐6736(03)14283‐3
Swedberg K, Pfeffer M, Granger C, McMurray J, Ohlin G, Olofsson B, et al. Candesartan in heart failure—Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm‐Programme Investigators. J Card Fail 1999;5:276‐282. doi:10.1016/s1071‐9164(99)90013‐1
Bots SH, Onland‐Moret NC, Tulevski II, van der Harst P, Cramer MJM, Asselbergs FW, et al. Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart 2021;107:1748‐1755. doi:10.1136/heartjnl‐2021‐319229
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz‐Zagrosek V, et al. Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study. Lancet 2019;394:1254‐1263. doi:10.1016/S0140‐6736(19)31792‐1
Cerlinskaite‐Bajore K, Lam CSP, Sliwa K, Adamo M, Ter Maaten JM, Léopold V, et al. Sex‐specific analysis of the rapid up‐titration of guideline‐directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG‐HF trial. Eur J Heart Fail 2023;25:1156‐1165. doi:10.1002/ejhf.2882
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J. Effects of sacubitril‐valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON‐HF. Circulation 2020;141:338‐351. doi:10.1161/CIRCULATIONAHA.119.044491
Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, et al. Efficacy and safety of sacubitril/valsartan by dose level achieved in the PIONEER‐HF trial. JACC Heart Fail 2020;8:834‐843. doi:10.1016/j.jchf.2020.06.008
Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). J Am Coll Cardiol 2002;40:491‐498. doi:10.1016/s0735‐1097(02)01970‐8
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222‐239. doi:10.2165/00003495‐199550020‐00003
Hirvensalo P, Tornio A, Launiainen T, Paile‐Hyvärinen M, Tapaninen T, Neuvonen M, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics—A comprehensive pharmacogenomic study. Clin Pharmacol Ther 2020;108:885‐895. doi:10.1002/cpt.1928
Cabaleiro T, Roman M, Ochoa D, Talegón M, Prieto‐Pérez R, Wojnicz A, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 2013;41:224‐229. doi:10.1124/dmd.112.046292
Marino MR, Vachharajani NN. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 2002;40:112‐122. doi:10.1097/00005344‐200207000‐00014
Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:S73‐S86. doi:10.1038/sj.jhh.1000991
McClellan KJ, Goa KL. Candesartan cilexetil: A review of its use in essential hypertension. Drugs 1998;56:847‐869. doi:10.2165/00003495‐199856050‐00013
Easthope SE, Jarvis B. Candesartan cilexetil: An update of its use in essential hypertension. Drugs 2002;62:1253‐1287. doi:10.2165/00003495‐200262080‐00016
Regitz‐Zagrosek V. Therapeutic implications of the gender‐specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006;5:425‐438. doi:10.1038/nrd2032
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM‐HF trial. Eur J Heart Fail 2016;18:1228‐1234. doi:10.1002/ejhf.580
Swat SA, Helmkamp LJ, Tietbohl C, Thompson JS, Fitzgerald M, McIlvennan CK, et al. Clinical inertia among outpatients with heart failure: Application of treatment nonintensification taxonomy to EPIC‐HF trial. JACC Heart Fail 2023;11:1579‐1591. doi:10.1016/j.jchf.2023.06.022
Ferreira JP, Konstam MA, McMurray JJV, Butler J, Girerd N, Rossignol P, et al. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: The HEAAL trial. Eur J Heart Fail 2021;23:1477‐1484. doi:10.1002/ejhf.2255
Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden). Eur J Heart Fail 2021;23:1499‐1511. doi:10.1002/ejhf.2271
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo‐Leiro MG, Harjola VP, et al. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: An analysis of the ESC Heart Failure Long‐Term Registry. Eur J Heart Fail 2017;19:1574‐1585. doi:10.1002/ejhf.813
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left‐ventricular ejection fraction: The CHARM‐Preserved trial. Lancet 2003;362:777‐781. doi:10.1016/S0140‐6736(03)14285‐7